Lumosa Therapeutics Co., Ltd. announced today (2024/1/22) that the Phase 2 trial for its LT3001, a novel treatment for acute ischemic stroke, has received approval from Germany, Spain, Italy, the Czech Republic, Greece, and Portugal, officially initiating a Phase II clinical trial with multiple doses in the US, Taiwan and six European countries.